|
| Exchange Disseminated Time 22/03/2016 18:53:15 | Cadila Healthcare Ltd has informed BSE that:
"There have been some reports regarding the pre-qualification plant inspection of the vaccines facility by WHO in terms of the possible linkage with our oral solids and injectable facilities at the Moraiya manufacturing complex.
In this regard, we hereby inform that we have a separate manufacturing facility for vaccines and this does not form a part of the oral solids and injectable facilities at Moraiya, which cater to the US markets. Regarding the anti-rabies vaccine manufactured at the vaccine facility we have already responded to WHO and have been implementing remedial measures. There is no significant impact on the business and there were no exports of this product to the US. Thus it does not impact our US business." |
|
|